Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21.116
Filtrar
1.
Bol. méd. postgrado ; 36(2): 21-25, dic.2020. tab, graf
Artigo em Espanhol | LILACS, LIVECS | ID: biblio-1117893

RESUMO

El síndrome de lisis tumoral (SLT) es una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación sistémica lo cual se asocia a graves trastornos del metabolismo hidroelectrolítico. Se realizó una revisión retrospectiva de historias clínicas con el objetivo de describir las características clínicas de los pacientes con sospecha de SLT que ingresaron al Servicio de Medicina Interna del Hospital General Universitario Dr. Luis Gómez López durante el lapso 2017-2018. El 50% de los pacientes tenían una edad comprendida entre 51 y 70 años, siendo el 65% de sexo femenino. Los canceres más frecuentemente encontrados fueron el cáncer de mama (29%), cáncer gástrico (15%) y el linfoma no Hodgkin (12%). Todos los pacientes presentaron al menos tres de las manifestaciones clínicas asociadas al SLT entre las cuales se encuentran náuseas, vómitos, anorexia, debilidad, calambres, hiperreflexia, oliguria, anuria, hematuria, hipotensión, convulsiones y deshidratación. El 46% de los pacientes presentaron hiperpotasemia, mientras que 36% mostraron hipocalcemia y 18% hiperfosfatemia. El 76% de los pacientes cursaron con una creatinina > 1,4 mg/dl. El diagnóstico definitivo de SLT no fue posible realizarlo en ninguno de los pacientes incluidos en este estudio debido a la falta de estudios paraclínicos necesarios para satisfacer los criterios según los lineamientos internacionales(AU)


Tumor lysis syndrome (TLS) is a potentially lethal complication due to massive release of nucleic acids, potassium and phosphate into the systemic circulation which is associated with severe hydroelectrolitic metabolic disorders. A retrospective review of clinical charts was performed in order to describe clinical characteristics of patients with possible TLS that were admitted to the Servicio de Medicina Interna of the Hospital General Universitario Dr. Luis Gómez López during the period 2017-2018. The results show that 50% of patients were between 51 and 70 years old and 65% were female. Breast cancer (29%), stomach cancer (15%) and Non-Hodgkin lymphoma (12%) were more frequent in patients with possible TLS. All patients showed at least three of the clinical features commonly associated with TLS such as nausea, vomiting, anorexia, weakness, cramps, hyperreflexia, oliguria, anuria, hematuria, hypotension, convulsion and dehydration. 46% of patients had hyperkalemia, 36% hypocalcemia and 18% hyperphosphatemia. Creatinine levels > 1,4 mg/dl were seen in 76% of patients. Definitive diagnosis of TLS was not possible in any of the patients included in this study due to the lack of laboratory studies required according to international guidelines(AU)


Assuntos
Humanos , Fosfatos , Potássio , Radioterapia , Neoplasias da Mama , Ácidos Nucleicos , Síndrome de Lise Tumoral/fisiopatologia , Tratamento Farmacológico , Prescrições de Medicamentos , Cuidados Críticos , Hematologia , Medicina Interna , Oncologia
2.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47859

RESUMO

Trabalho vencedor cria possibilidade de redução de custos em procedimento de tratamento contra leucemia


Assuntos
Institutos de Câncer , Inovação , Oncologia
3.
J Exp Clin Cancer Res ; 39(1): 177, 2020 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-32873322

RESUMO

BACKGROUND: A pronounced polarization of healthcare resources and workforce towards the prevention of the rapid spread of SARS-CoV-2 occurred at the expenses of the majority of chronic diseases and cancer, thus jeopardizing continuity of care and therapy outcomes. In this challenging and overwhelming scenario, our Institute confirmed its mission to provide expert cancer care. Here, we provide a report of strategic decisions made and of articulated measures developed to limit virus spreading while striving to make our hospital closer to patients. CONCLUSIONS: We hope our experience may serve as a resource to inform clinical care models in case of future epidemiological outbreaks.


Assuntos
Betacoronavirus/patogenicidade , Doença Crônica/epidemiologia , Infecções por Coronavirus/epidemiologia , Oncologia/tendências , Pneumonia Viral/epidemiologia , Benchmarking , Infecções por Coronavirus/virologia , Humanos , Pandemias , Pneumonia Viral/virologia , Fatores de Risco
4.
Eur J Cancer ; 137: 235-239, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32805640

RESUMO

The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19-positive patients with cancer enrolled in such trials. We notably present the risks and challenges raised by COVID-19-infected phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. We finally propose some guidelines for the conduct of phase 1 trials and management of COVID-19-infected patients in a pandemic time.


Assuntos
Antineoplásicos/efeitos adversos , Ensaios Clínicos Fase I como Assunto/normas , Infecções por Coronavirus/terapia , Neoplasias/tratamento farmacológico , Seleção de Pacientes , Pneumonia Viral/terapia , Betacoronavirus/imunologia , Betacoronavirus/isolamento & purificação , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/imunologia , Infecções por Coronavirus/virologia , Medicina Baseada em Evidências/normas , Humanos , Controle de Infecções/normas , Oncologia/normas , Neoplasias/imunologia , Pandemias , Pneumonia Viral/epidemiologia , Pneumonia Viral/imunologia , Pneumonia Viral/virologia , Guias de Prática Clínica como Assunto , Resultado do Tratamento
6.
JCO Glob Oncol ; 6: 1298-1305, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32795196

RESUMO

PURPOSE: As a result of their immunocompromised status associated with disease and treatment, patients with cancer face a profound threat for higher rates of complications and mortality if they contract the coronavirus disease 2019 infection. Medical oncology communities have developed treatment modifications to balance the risk of contracting the virus with the benefit of improving cancer-related outcomes. METHODS: We systemically examined our community cancer center database to display patterns of change and to unveil factors that have been considered with each decision. We studied a cohort of 282 patients receiving treatment and found that 159 patients (56.4%) had treatment modifications. RESULTS: The incidence of treatment modification was observed in patients undergoing adjuvant and neoadjuvant (41.4%), palliative (62.9%), or injectable endocrine or bone-modulating only (76.0%) treatments. Modifications were applied to regimens with myelosuppressive (56.5%), immunosuppressive (69.2%), and immunomodulating (61.5%) potentials. These modifications also affected intravenous (54.9%) and subcutaneous injectable treatments (62.5%) more than oral treatments (15.8%). Treatment modifications in 112 patients (70.4%) were recommended by providers, and 47 (29.6%) were initiated by patients. The most common strategy of modification was to skip or postpone a scheduled treatment (49%). Among treatment with no modifications, treatment regimens were maintained in patients who tolerated treatment well (37.0%), in treatments with curative intent (22%), and in symptomatic patients who required treatment (14%). CONCLUSION: Our observation and analysis suggested that the primary goal of treatment modification was to decrease potential exposure. The pattern also reflected the negative impact of the pandemic on health care providers who initiated these changes. Providers have to consider individualized recommendations incorporating multiple factors, such as tolerance, potential toxicity, treatment nature and route, and disease severity.


Assuntos
Antineoplásicos/administração & dosagem , Betacoronavirus , Infecções por Coronavirus , Neoplasias/terapia , Pandemias , Pneumonia Viral , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Centros Comunitários de Saúde , Feminino , Humanos , Masculino , Oncologia/normas , Pessoa de Meia-Idade , Terapia Neoadjuvante , Neoplasias/patologia , Cidade de Nova Iorque , Cuidados Paliativos/métodos , Aceitação pelo Paciente de Cuidados de Saúde
7.
ESMO Open ; 5(4)2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32847836

RESUMO

BACKGROUND: COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. Here we analysed measures taken in major oncological units in Europe and the USA. METHODS: A 46-item survey was sent by email to representatives of 30 oncological centres in 12 of the most affected countries. The survey inquired about preventive measures established to reduce virus spread, patient education and processes employed for risk reduction in each oncological unit. RESULTS: Investigators from 21 centres in 10 countries answered the survey between 10 April and 6 May 2020. A triage for patients with cancer before hospital or clinic visits was conducted by 90.5% of centres before consultations, 95.2% before day care admissions and in 100% of the cases before overnight hospitalisation by means of phone calls, interactive online platforms, swab test and/or chest CT scan. Permission for caregivers to attend clinic visits was limited in many centres, with some exceptions (ie, for non-autonomous patients, in the case of a new diagnosis, when bad news was expected and for terminally ill patients). With a variable delay period, the use of personal protective equipment was unanimously mandatory, and in many centres, only targeted clinical and instrumental examinations were performed. Telemedicine was implemented in 76.2% of the centres. Separated pathways for COVID-19-positive and COVID-19-negative patients were organised, with separate inpatient units and day care areas. Self-isolation was required for COVID-19-positive or symptomatic staff, while return to work policies required a negative swab test in 76.2% of the centres. CONCLUSION: Many pragmatic measures have been quickly implemented to deal with the health emergency linked to COVID-19, although the relative efficacy of each intervention should be further analysed in large observational studies.


Assuntos
Institutos de Câncer/organização & administração , Infecções por Coronavirus/prevenção & controle , Neoplasias/terapia , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Betacoronavirus , Institutos de Câncer/estatística & dados numéricos , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Assistência à Saúde , Desinfecção , Europa (Continente)/epidemiologia , Pesquisas sobre Serviços de Saúde , Humanos , Oncologia/estatística & dados numéricos , Equipamento de Proteção Individual , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Triagem , Estados Unidos/epidemiologia , Visitas a Pacientes
8.
Med Oncol ; 37(10): 85, 2020 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-32808089

RESUMO

Management of patients with head and neck cancers (HNCs) is challenging for the Radiation Oncologist, especially in the COVID-19 era. The Italian Society of Radiotherapy and Clinical Oncology (AIRO) identified the need of practice recommendations on logistic issues, treatment delivery and healthcare personnel's protection in a time of limited resources. A panel of 15 national experts on HNCs completed a modified Delphi process. A five-point Likert scale was used; the chosen cut-offs for strong agreement and agreement were 75% and 66%, respectively. Items were organized into two sections: (1) general recommendations (10 items) and (2) special recommendations (45 items), detailing a set of procedures to be applied to all specific phases of the Radiation Oncology workflow. The distribution of facilities across the country was as follows: 47% Northern, 33% Central and 20% Southern regions. There was agreement or strong agreement across the majority (93%) of proposed items including treatment strategies, use of personal protection devices, set-up modifications and follow-up re-scheduling. Guaranteeing treatment delivery for HNC patients is well-recognized in Radiation Oncology. Our recommendations provide a flexible tool for management both in the pandemic and post-pandemic phase of the COVID-19 outbreak.


Assuntos
Betacoronavirus , Infecções por Coronavirus/prevenção & controle , Neoplasias de Cabeça e Pescoço/radioterapia , Oncologia/normas , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Guias de Prática Clínica como Assunto/normas , Infecções por Coronavirus/epidemiologia , Neoplasias de Cabeça e Pescoço/epidemiologia , Humanos , Itália/epidemiologia , Oncologia/métodos , Pneumonia Viral/epidemiologia , Radioterapia/métodos , Radioterapia/normas , Sociedades Médicas/normas
9.
Urologe A ; 59(9): 1026-1034, 2020 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-32821957

RESUMO

In the past 10 years, the methods of artificial intelligence (AI) have experienced breakthroughs that have opened up a multitude of new fields of application for information technology. AI is particularly strong in those areas where patterns have to be recognized and conclusions and forecasts based on large, multiparametric data sets have to be drawn. Computers are superior to us in terms of precision and speed in these problems. These advances in information technology reach us at a time when innovations in diagnostics and sensor technology enable more precise patient stratification and confront medical personnel with an increasing quantity and quality of patient data. Urology is symbolic of this new complexity of medicine, in which multi-layered diagnostic cascades require a high degree of interdisciplinarity and, especially in uro-oncology, therapeutic strategies are becoming more differentiated and require the interpretation of multiple clinical and diagnostic data. Here, methods of Artificial Intelligence will in future support medical personnel in diagnostics and therapy decisions and thus come closer to the goal of precision medicine. A prerequisite for the success of AI-based support tools will be the transparent development and validation of the software, as well as the population-based visualization of decision parameters.


Assuntos
Inteligência Artificial , Urologistas , Urologia/tendências , Humanos , Oncologia/tendências , Medicina de Precisão , Software
10.
Neurol India ; 68(4): 769-773, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32859812

RESUMO

The entire world including India is currently fighting the coronavirus disease 19 (COVID-19) pandemic that threatens to disrupt healthcare systems globally in terms of capacity and resources. This outbreak necessitates an urgent review of existing management guidelines for commonly encountered tumors of the brain and central nervous system (CNS). Such a review should include a reassessment of benefit-risk ratio to align with local, national, and international priorities without compromising on delivery of care in terms of safety, compassion, efficiency, and effectiveness. Towards this end, the Indian Society of Neuro-Oncology (ISNO) constituted an online expert panel with adequate representation from all major treatment modalities (neuro-surgery, radiation oncology, and pediatric/medical oncology) to formulate a "COVID-19 context" position statement to guide the care of neuro-oncology patients during the ongoing crisis. The ISNO position statement suggests graded prioritization (based on clinical presentation, type of tumor, expected prognosis, and relevance of immediate therapy) for efficient utilization of resources and provides a framework through a set of general considerations, treatment modality-based considerations, and disease-specific considerations for the guidance of healthcare professionals involved in the delivery of care and services to patients with CNS tumors. The views expressed herein represent the current consensus of key opinion leaders from within the Indian neuro-oncology community and should not be in any case considered binding medically or legally to individual physicians and/or hospitals who may formulate their guidelines based on local setup and health-environment and update them periodically based on emerging evidence through the COVID-19 pandemic.


Assuntos
Betacoronavirus/patogenicidade , Neoplasias do Sistema Nervoso Central/terapia , Infecções por Coronavirus/complicações , Oncologia/normas , Pneumonia Viral/complicações , Consenso , Humanos , Índia , Pandemias
11.
J BUON ; 25(3): 1277-1280, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32862566

RESUMO

To protect cancer patients from COVID-19 exposure, prioritization strategies are being implemented at global level. Measures include use of tele-health services, deferring elective surgeries, delaying non life-saving therapies, interrupting maintenance and supportive care regimens and suspending screening and regular follow-up visits. Nonetheless, the risk of infection may not always outweigh oncology treatment benefit. Lives of most oncology patients depend on their ability to receive medical, surgical and radiotherapy care. Postponing screening, follow-up and radical surgeries increase patients' risk of developing metastatic disease. A viral pandemic lasts long time and exhibits seasonal and geographical variations. Though vaccines will be available only in the 2021, a global, aggressive, all-embracing and protracted slowdown of oncologic activities will severely jeopardize patients' outcomes. A present international oncologists' panel, ECPC and FAVO, strongly suggest that Hospital measures in a specific geographical area/Nation should be in line with the local epidemic, and restrictions adopted should be adapted and stratified over time.


Assuntos
Infecções por Coronavirus/prevenção & controle , Saúde Global , Neoplasias/mortalidade , Neoplasias/terapia , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Controle de Doenças Transmissíveis/organização & administração , Infecções por Coronavirus/epidemiologia , Europa (Continente)/epidemiologia , Humanos , Oncologia/organização & administração , Pandemias/estatística & dados numéricos , Pneumonia Viral/epidemiologia , Guias de Prática Clínica como Assunto , Medição de Risco , Análise de Sobrevida , Telemedicina/organização & administração
13.
BMC Med Res Methodol ; 20(1): 209, 2020 08 12.
Artigo em Inglês | MEDLINE | ID: mdl-32787822

RESUMO

BACKGROUND: As the whole world is experiencing the cascading effect of a new pandemic, almost every aspect of modern life has been disrupted. Because of health emergencies during this period, widespread fear has resulted in compromised patient safety, especially for patients with cancer. It is very challenging to treat such cancer patients because of the complexity of providing care and treatment, along with COVID-19. Hence, an effective treatment comparison strategy is needed. We need to have a handy tool to understand cancer progression in this unprecedented scenario. Linking different events of cancer progression is the need of the hour. It is a huge challenge for the development of new methodology. METHODS: This article explores the time lag effect and makes a statistical inference about the best experimental arm using Accelerated Failure Time (AFT) model and regression methods. The work is presented as the occurrence of other events as a hazard rate after the first event (relapse). The time lag effect between the events is linked and analysed. RESULTS: The results were presented as a comprehensive analytical strategy by joining all disease progression. An AFT model applied with the transition states, and the dependency structure between the gap times was used by the auto-regression model. The effects of arms were compared using the coefficient of auto-regression and accelerated failure time (AFT) models. CONCLUSIONS: We provide the solutions to overcome the issue with intervals between two consecutive events in motivating head and neck cancer (HNC) data. COVID-19 is not going to leave us soon. We have to conduct several cancer clinical trials in the presence of COVID-19. A comprehensive analytical strategy to analyse cancer clinical trial data during COVID-19 pandemic is presented.


Assuntos
Algoritmos , Infecções por Coronavirus/prevenção & controle , Neoplasias de Cabeça e Pescoço/terapia , Oncologia/métodos , Modelos Teóricos , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Teorema de Bayes , Betacoronavirus/fisiologia , Infecções por Coronavirus/complicações , Infecções por Coronavirus/virologia , Progressão da Doença , Neoplasias de Cabeça e Pescoço/complicações , Neoplasias de Cabeça e Pescoço/diagnóstico , Humanos , Estimativa de Kaplan-Meier , Cadeias de Markov , Método de Monte Carlo , Recidiva Local de Neoplasia , Pneumonia Viral/complicações , Pneumonia Viral/virologia
16.
Lancet Oncol ; 21(8): e398-e404, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32758477

RESUMO

Immune checkpoint inhibitors (ICIs) have now been approved in numerous and diverse cancer types and combination regimens. Effective recognition and treatment of ICI toxicities, which might occur acutely, affect any organ system, and produce many distinct clinical syndromes, have emerged as essential goals of ICI management. Thus, developing robust diagnostic and management approaches for ICI toxicity across the health-care system is an urgent and unmet clinical need. In this Personal View, we describe barriers to high-quality care that have constrained the most effective management of patients with cancer receiving ICI treatment. We review education initiatives to enhance patient and physician awareness, which is necessary given the broad spectrum of ICI toxicities often experienced by patients, and assess various systems-based approaches that maximise the chances of appropriate management. In addition, we describe research pipelines that broaden evidence-based approaches and the pathobiology of these novel events. Developing effective, systematic approaches for the recognition and treatment of ICI toxicities will continue to grow in importance as these agents proliferate in cancer care.


Assuntos
Antineoplásicos Imunológicos/efeitos adversos , Neoplasias/tratamento farmacológico , Humanos , Oncologia/educação , Assistência ao Paciente/métodos , Educação de Pacientes como Assunto/métodos
17.
Med Oncol ; 37(9): 80, 2020 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-32767203

RESUMO

Cancer patients are at particular risk from COVID-19 since they usually present multiple risk factors for this infection such as older age, immunosuppressed state, comorbidities (e.g., chronic lung disease, diabetes, cardiovascular diseases), need of frequent hospital admissions and visits. Therefore, in the COVID era, oncologists should carefully weigh risks/benefits when planning cancer therapies and follow-up appointments. Recently, several scientific associations developed specific guidelines or recommendations to help physicians in their clinical practice. This review focuses on main available guidelines/recommendations regarding the cancer patient management during the COVID-19 pandemic.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Internacionalidade , Oncologia/normas , Neoplasias/epidemiologia , Pneumonia Viral/epidemiologia , Guias de Prática Clínica como Assunto/normas , Infecções por Coronavirus/terapia , Humanos , Oncologia/métodos , Neoplasias/terapia , Pandemias , Pneumonia Viral/terapia
18.
Med Oncol ; 37(9): 83, 2020 Aug 09.
Artigo em Inglês | MEDLINE | ID: mdl-32772185

RESUMO

The COVID-19 pandemic has deeply impacted the activity of interventional oncology in cancer centers. Since the first COVID case was diagnosed in Italy on February 21st, our Hospital, located in Milan downtown, has been at the frontline to manage this emergency and to try to ensure essential services. In the present article, we discuss the changes that need to be done for the organization, safety, and patient management in interventional oncology.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Oncologia/normas , Neoplasias/epidemiologia , Pneumonia Viral/epidemiologia , Centros de Atenção Terciária/normas , Infecções por Coronavirus/terapia , Pessoal de Saúde/normas , Humanos , Itália/epidemiologia , Oncologia/métodos , Neoplasias/terapia , Pandemias , Equipamento de Proteção Individual/normas , Pneumonia Viral/terapia , Fluxo de Trabalho
19.
JCO Glob Oncol ; 6: 1248-1257, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32755479

RESUMO

PURPOSE: To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic. METHODS: An online survey was conducted between March 24 and April 29, 2020. RESULTS: A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease. CONCLUSION: Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.


Assuntos
Betacoronavirus/patogenicidade , Tomada de Decisão Clínica , Infecções por Coronavirus/prevenção & controle , Controle de Infecções/estatística & dados numéricos , Neoplasias/terapia , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Adulto , Idoso , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/virologia , Feminino , Humanos , Controle de Infecções/métodos , Controle de Infecções/normas , Transmissão de Doença Infecciosa do Paciente para o Profissional/prevenção & controle , Transmissão de Doença Infecciosa do Profissional para o Paciente/prevenção & controle , Masculino , Oncologia/métodos , Oncologia/normas , Oncologia/estatística & dados numéricos , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Oncologistas/estatística & dados numéricos , Equipamento de Proteção Individual/normas , Equipamento de Proteção Individual/estatística & dados numéricos , Pneumonia Viral/epidemiologia , Pneumonia Viral/transmissão , Pneumonia Viral/virologia , Padrões de Prática Médica/normas , Padrões de Prática Médica/estatística & dados numéricos , Inquéritos e Questionários/estatística & dados numéricos , Telemedicina/estatística & dados numéricos
20.
Enferm. foco (Brasília) ; 11(2): 89-95, jul. 2020.
Artigo em Português | LILACS, BDENF - Enfermagem | ID: biblio-1104178

RESUMO

Objetivo: Conhecer as percepções de enfermeiros sobre o cuidado a pacientes oncológicos, na Atenção Primária à Saúde. Metodologia: Pesquisa descritiva, com abordagem qualitativa, realizada entre março e abril de 2019, em dez Unidades de Atenção Primária à Saúde, no município de Aracati, Ceará, Brasil. Os sujeitos da pesquisa foram 10 enfermeiros, sendo realizada entrevista semiestruturada registrada em formulário. Resultados: A partir das falas, emergiram três categorias: Percepções de enfermeiros sobre câncer e cuidados a pacientes oncológicos; Ações realizadas na atenção primária no cuidado a pacientes oncológicos; Dificuldades na assistência oncológica, na atenção primária. Conclusão: Os enfermeiros participantes visualizaram o câncer como doença estigmatizante, que interfere na qualidade de vida de pacientes e familiares, sendo importante a assistência oncológica no âmbito da atenção primária, principalmente, com auxílio de equipe multiprofissional. (AU)


Objective: To know the perceptions of nurses about the care of cancer patients in Primary Health Care. Methodology: Descriptive research, with a qualitative approach, carried out between March and April 2019, in ten Primary Health Care Units, in the municipality of Aracati, Ceará, Brazil. The research subjects were 10 nurses, and a semi-structured interview was conducted, using a form. Results: From the speeches, three categories emerged: Nurses' perceptions about cancer and care for cancer patients; Actions carried out in primary care in the care of cancer patients; Difficulties in cancer care, in primary care. Conclusion: Participating nurses viewed cancer as a stigmatizing disease, which interferes with the life quality of patients and family members, and it is important to provide cancer care in primary care, especially with the help of a multidisciplinary team. (AU)


Objetivo: Conocer las percepciones de las enfermeras sobre la atención a pacientes con cáncer en Atención Primaria de Salud. Metodología: Investigación descriptiva, con enfoque cualitativo, realizada entre marzo y abril de 2019, en diez Unidades de Atención Primaria de Salud, en el municipio de Aracati, Ceará, Brasil. Los sujetos de investigación fueron 10 enfermeras, con una entrevista semiestructurada, utilizando una forma. Resultados: De los discursos, surgieron tres categorías: las percepciones de las enfermeras sobre el cáncer y la atención a los pacientes con cáncer; Acciones realizadas en atención primaria en la atención de pacientes con cáncer; Dificultades en la atención del cáncer, en atención primaria. Conclusión: Los enfermeros participantes vieron el cáncer como una enfermedad estigmatizante, que interfiere con la calidad de vida de los pacientes y sus familiares, y es importante brindar atención del cáncer en la atención primaria, especialmente con la ayuda de un equipo multidisciplinario. (AU)


Assuntos
Atenção Primária à Saúde , Pacientes , Oncologia , Cuidados de Enfermagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA